期刊文献+

血脂康对冠心病患者餐后血清脂蛋白(a)浓度的影响研究 被引量:4

Effect of Xuezhikang on Postprandial Serum Lipoprotein (a) Concentrations in Patients with Coronary Heart Disease
下载PDF
导出
摘要 目的血清脂蛋白(a)[Lp(a)]浓度升高被认为是冠心病的独立危险因素之一。探讨血脂康对冠心病患者空腹与高脂餐后血清Lp(a)浓度的影响。方法50例病情稳定的冠心病患者,经饮食宣教4周后,进行高脂餐负荷试验(总热量为800kcal,其中脂肪50g)。分别于空腹与餐后2、4、6h采集外周静脉血标本,测定血清Lp(a)浓度。将患者随机分为对照组和血脂康组,各25例。治疗6周后重复上述高脂餐负荷试验并测定血清Lp(a)浓度。结果冠心病患者高脂餐后2、4、6h血清Lp(a)和三酰甘油浓度较高脂餐前显著升高,差异有统计学意义(P<0.05)。经血脂康治疗6周后,血脂康组的空腹与餐后各时间点血清Lp(a)和三酰甘油浓度较对照组显著降低,差异均有统计学意义(P<0.01)。结论冠心病患者高脂餐后血清Lp(a)浓度显著升高,血脂康能有效降低冠心病患者空腹与餐后血清Lp(a)浓度。 Objective Elevated serum lipoprotein (a)[Lp(a)] concentration is regarded as an independent risk factor for coronary heart disease(CHD).To explore the effect of Xuezhikang on fasting and postprandial Lp(a) concentrations in patients with CHD.Methods Fifty CHD patients with stable condition after four-week diet control were recruited for high-fat meal test (the total calorie was 800 kcal,including 50g fat).The peripheral blood samples were collected in the fasting state and at 2,4 and 6h after a high fat meal to test the serum Lp(a) concentration.Then 50 CHD patients were randomly divided as Xuezhikang group and control group,with 25 in each.Then,six weeks later,the high-fat meal test and the assay of serum Lp(a) concentration were repeated.Results The postprandial serum Lp(a) and triglyceride concentrations significantly increased at 2,4 and 6h after a high-fat meal that at baseline (P<0.05).After 6-week treatment with Xuezhikang the postprandial Lp(a) and triglyceride concentrations were significantly decreased in Xuezhikang group than in control group (P<0.01).Conclusion The serum Lp(a) concentration after a high fat meal is remarkably increased in CHD patients,Xuezhikang can effectively reduce the fasting and postprandial Lp(a) concentrations.
出处 《中国全科医学》 CAS CSCD 北大核心 2010年第12期1282-1284,共3页 Chinese General Practice
关键词 冠心病 脂蛋白(a) 血脂康 饭间期间 Coronary heart disease Lipoprotein(a) Xuezhikang Postprandial period
  • 相关文献

参考文献16

  • 1刘永煌,李再平,以淑君,李贵芳,徐丽芸,王秀容,蒋晓梅,郭丛兰.老年2型糖尿病患者脂肪餐负荷后脂蛋白(a)水平变化[J].中国临床康复,2005,9(35):64-65. 被引量:1
  • 2Karatay S,Yildirim K,Uyanik A,et al.Increased serum concentrations of homocysteine and lipoprotein(a) in familial Mediterranean fever[J].Ann Clin Lab Sci,2010,40(1):10-14.
  • 3Schaefer EJ,McNamara JR,Tayler T,et al.Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects[J].Am J Cardiol,2002,90(7):689-696.
  • 4Hoppichler F,Kraft HG,Sandholzer C,et al.Lipoprotein(a) is increased in triglyceride-rich lipoproteins in men with coronary heart disease,but does not change acutely following oral fat ingestion[J].Atherosclerosis,1996,122(1):127-134.
  • 5Ishikawa T,Yamashita T,Mochizuki K,et al.Changes in the concentration and distribution of lipoprotein (a) in plasma after fat intake[J].J Atheroscler Thromb,1995,2(Suppl 1):S17-S21.
  • 6Reblin T,Rader DJ,Beisiegel U,et al.Correlation of apolipoprotein(a) isoproteins with Lp(a) density and distribution in fasting plasma[J].Atherosclerosis,1992,94(2-3):223-232.
  • 7Gaubatz JW,Hoogeveen RC,Hoffman AS,et al.Isolation,quantitation,and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins[J].J Lipid Res,2001,42(1):2058-2068.
  • 8Galvano F,Li Volti G,Malaguarnera M,et al.Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus[J].Expert Opin Pharmacother,2009,10(12):1875-1882.
  • 9迟东升,靳风霞,杨曙光,苏玉文,葛斌,张杰,张燕,刘伊丽.高脂血症患者C-反应蛋白含量的变化及氟伐他汀对它的影响[J].第一军医大学学报,2002,22(12):1109-1111. 被引量:4
  • 10Jenner JL,Jacques PF,Seman LJ,et al.Ascorbic acid supplementation does not lower plasma lipoprotein(a) concentrations[J].Atherosclerosis,2000,151(2):541-544.

二级参考文献22

  • 1侯泽,崔玉鲜,沃兴德,刘德文.老年2型糖尿病患者血清脂蛋白(a)水平与载脂蛋白(a)基因多态性分析[J].中国动脉硬化杂志,2001,9(3):223-226. 被引量:12
  • 2刘永煌,王秀容,李贵芳,蒋晓梅,李再平,郭丛兰,李俐,徐丽芸.老年糖尿病患者脂肪餐后脂代谢变化的特征[J].中国临床康复,2004,8(36):8224-8225. 被引量:2
  • 3沈志卫,于普林,孙美珍,迟家敏,周玉芳,朱晓单,杨超元,何存芳.血脂康治疗原发性高脂血症的前瞻性研究[J].中华医学杂志,1996,76(2):156-157. 被引量:91
  • 4Arz W, Wieland H. HMG-CoA reductase inhibition: anti-inflamma tory effects beyond lipid lowering[J]? Herz, 2000, 25(2): 117-25.
  • 5Blake GJ, Ridker PM. Novel clinical markers of vascular wall in fammation[J]. Circ Res, 2001, 89(9): 763-71.
  • 6Langtry HD, Markham A. Fluvastatin: a review of its use in lipid disorders[J]. Drugs, 1999, 57(4): 583-606.
  • 7Marz W, Scharnagl H, Abletshauser C, et al. Fluvastatin lowers athero genic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype [J]. Circulation, 2001,103(15): 1942-8.
  • 8Bickel C, Rupprecht HJ, Blankenberg S, et al. Influence of HMGCoA reductase inhibitors on markers of coagulation, systemic in flammation and soluble cell adhesion[J]. Int J Cardiol, 2002, 82(1): 25-31.
  • 9Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evalua tion (PRINCE): a randomized trial and cohort study [J]. JAMA, 2001, 286(1): 64-70.
  • 10Strandberg TE, Vanhanent H, Tikkanen MJ. Associations between changes in C-reactive protein and serum lipids during statin treat ment[J]. Ann Med, 2000, 32(4): 579-83.

共引文献5

同被引文献49

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部